MedPath

The success rate of clarithromycin and furazolidone treatment regimen with or without using pyloshot in patients with refractory Helicobacter pylori infectio

Phase 3
Conditions
Helicobacter Pylori.
Registration Number
IRCT20230827059273N1
Lead Sponsor
Ardabil University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
272
Inclusion Criteria

Patients with treatment-resistant Helicobacter pylori infection who still have positive fecal antigen despite treatment.

Exclusion Criteria

Pregnant and lactating women

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Helicobacter pylori fecal antigen negativity after two months of treatment. Timepoint: H. pylori fecal antigen measurement once two months after the end of treatment. Method of measurement: Stool test.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath